Scientists share promising results of BET and EZH2 inhibitors for lymphoma
Researchers at the TAT (Targeted Anticancer Therapies) International Congress 2018…
Researchers at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris have presented new epigenetics compounds that show early activity in lymphoma patients.